Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment.

摘要: The DNA Mismatch Repair (MMR) pathway is a fundamental cellular process required to repair mispaired bases introduced routinely during replication. Given this critical role in the maintenance of genome stability, it not surprising that underlying defects MMR occur both hereditary and sporadic cancers. Furthermore, status greatly influences sensitivity cells many common chemotherapeutic agents. Therefore, novel strategies are being investigated exploit loss these cancers identify personalized therapeutic target deficient tumours. In review, we describe recent advances tumours using synthetic lethal approach. We discuss new ways mutations secondary deficiency suggest potential therapies optimise treatment outcome. highlight ongoing clinical studies focussing on preventing treating